Article
Systematic in vivo candidate evaluation uncovers therapeutic targets for LMNA dilated cardiomyopathy and risk of Lamin A toxicity.
Journal of translational medicine - 16 Oct 2023
Tan Chia Yee, Chan Pui Shi, Tan Hansen, Tan Sung Wei, Lee Chang Jie Mick, Wang Jiong-Wei, Ye Shu, Werner Hendrikje, Loh Ying Jie, Lee Yin Loon, Ackers-Johnson Matthew, Foo Roger S Y, Jiang Jianming
Abstract excerpt
BACKGROUND: Dilated cardiomyopathy (DCM) is a severe, non-ischemic heart disease which ultimately results in heart failure (HF). Decades of research on DCM have revealed diverse aetiologies. Among them, familial DCM is the major form of DCM, with pathogenic variants in LMNA being the second most common form of autosomal dominant DCM. LMNA DCM is a multifactorial and complex disease with no specific treatment thus...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.